Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Company to provide updates on Mino-Lok Phase 3 trial and other key initiatives

Conference call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET

CRANFORD, NJ, Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on the development and commercialization of critical care products, today announced that it will host an investor call to discuss recent and upcoming developments, including topline results from the Phase 3 trial of Mino-Lok^®.

The conference call is scheduled for Tuesday, August 13, 2024, at 8:30 AM ET. Citius Chairman and CEO Leonard Mazur will be joined by members of the management team to discuss the Mino-Lok Phase 3 trial results, as well as other key initiatives.

To participate in the conference call, please dial 1-877-423-9813 (domestic) or 1-201-493-6779 (international) and reference conference ID 388327. A live webcast of the conference call will also be available on the Investors section of Citius' website at https://ir.citiuspharma.com.

A replay of the webcast will be available on Citius' website for 30 days following the call.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. focuses on the development and commercialization of critical care products, with a specific focus on anti-infectives, cancer care, and critical care injectables. The Company's product portfolio includes Mino-Lok^®, a novel, broad-spectrum antibiotic lock solution for the prevention of catheter-related bloodstream infections; Cetrorelix^®, an injectable gonadotropin-releasing hormone antagonist for the treatment of infertility; and Elaprase^®, an enzyme replacement therapy for the treatment of Hunter syndrome. Citius also has a number of other product candidates in development, including iclaprim, a novel antibiotic for the treatment of serious bacterial infections; Mino-Wrap^®, an antibiotic-eluting wound dressing; and CTI-120, a novel cancer immunotherapy.

For more information, please visit www.citiuspharma.com.

Media Contact:
Citius Pharmaceuticals, Inc.
(908) 925-1200
corpcomm@citiuspharma.com Investor Contact:
ICR Westwicke
Stephanie Carrington
(646) 277-1282
stephanie.carrington@westwicke.com